SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Company now focused on the development of ONCR-021, Oncorusβ lead self-amplifying RNA product candidate for...
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies...
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry...
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Oncorus (ONCR - Research Report), with a price...
0001671818P3Yfalse--12-31Q30001671818us-gaap:CommercialPaperMember2022-09-3000016718182021-02-170001671818us-gaap:RestrictedStockMember2022-01-01...
0001671818false0001671818dei:FormerAddressMember2022-11-022022-11-0200016718182022-11-022022-11-02 UNITED STATESSECURITIES AND...
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE...
ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies...
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies...
0001671818false00016718182022-09-132022-09-13 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.